AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01532297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CiDi)
Description: Use during chronic dialysis 3x/week
Study NCT01532297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dialysate (StDi)
Description: Use during chronic dialysis 3x/week
Study NCT02877147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEBTC
Description: SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
Study NCT02836847 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biological test
Description: mutation and signal pathway activation status analysis
Study NCT02836847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biological test
Description: mutation and signal pathway activation status analysis
Study NCT00744302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physiological (1.25 mmol/L ) calcium dialysate
Description: Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
Study NCT00744302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: physiological (1.25 mmol/L ) calcium dialysate
Description: Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GEMOX
Description: Conventional chemotherapy:gemcitabine and oxaliplatin
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: Conventional chemotherapy:gemcitabine and oxaliplatin
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT03991039 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gamma knife
Description: Microvascular decompression
Study NCT01486433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg (1 tablet) simvastatin once a day
Study NCT02200198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Description: Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Study NCT02200198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
Study NCT01486433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 mg (1 tablet) simvastatin once a day
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT01486433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA)
Description: 81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
Study NCT01486433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid (ASA)
Description: 81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
Study NCT02836847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Study NCT04724473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin Cream 0.025%
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT04724473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin Cream 0.025%
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT04724473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin Cream 0.025%
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT00408967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucotuzumab celmoleukin (EMD 273066)
Study NCT00374244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimozide
Description: half of the subjects are randomized to the active drug group
Study NCT00374244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: half of the subjects are randomized to placebo group
Study NCT01501279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Description: the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
Study NCT01232699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Obesity Treatment
Description: Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
Study NCT01232699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Obesity Treatment with MI
Description: In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
Study NCT01486433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
Study NCT01232699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent MI
Description: Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
Study NCT02200198 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
Study NCT04040322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV infusion
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Study NCT03410511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine free intake
Description: The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
Study NCT03410511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine intake
Description: The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
Study NCT04040322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iloprost Injection, for intravenous use
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Study NCT01883271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobic interval training
Description: Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
Study NCT01883271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous moderate intensity exercise
Description: Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
Study NCT00574236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341, doxorubicin
Description: bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
Study NCT03598517 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose chemoradiotherapy
Description: Radiation therapy: 60 Gy at 2 Gy/Fx/d over 6 weeks, immediately followed by 28.8 Gy in 24 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 88.8 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy is planned 6 weeks after high dose chemoradiation.
Study NCT03370705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: Sulodexide 250 ULS twice daily per oral route
Study NCT03672604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NLY01
Description: NLY01, a PEGylated form of the anti-diabetic peptide exenatide
Study NCT01799330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Muscle Stimulation (TCEMS)
Study NCT01799330 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham TCEMS
Description: Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response
Study NCT01732978 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Crying record
Description: Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff
Study NCT02911597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
Study NCT03370705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statin 20mg once daily per oral route,
Study NCT03410511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation intake
Description: The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
Study NCT03082560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Boston Grade of Activity in Lichen Planopilaris
Description: A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
Study NCT03657719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3114
Description: High-dose Quadrivalent influenza vaccine
Study NCT00839605 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
Study NCT03657719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Quadrivalent
Description: Quadrivalent influenza vaccine
Study NCT02149810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automatic Self Transcending Meditation
Description: as above
Study NCT01576042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: amiodarone
Description: The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Study NCT01576042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sotalol
Description: The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Study NCT01576042 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biosense Webster's NAVI-STAR Thermo-Cool
Description: The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
Study NCT04150627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep breathing
Description: Deep breathing maneuver to increase parasympathetic nerve activity
Study NCT03206177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Galunisertib 150mg po BID day 4-17
Study NCT03206177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Day 1: Paclitaxel 175 mg/m2 over 3 hours
Study NCT03206177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Day 1: Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)
Study NCT02058797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coherence Therapy
Description: Manualized individual treatment (3 + 1 one-hour sessions)
Study NCT02058797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Manualized individual treatment (3 + 1 one-hour sessions)
Study NCT00724230 — intervention group
Intervention type: DRUG
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks.
Study NCT00724230 — intervention group
Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
Study NCT04328597 — intervention group
Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Description: Inguinal hernia repair (open, laparo-endoscopic, robotic)
Study NCT00675597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)
Description: Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
Study NCT00004183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT04146922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step down to oral antimicrobial therapy
Description: Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
Study NCT04146922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV antimicrobial therapy
Description: No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
Study NCT02104284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: methacholine and mannitol bronchial challenge tests
Description: Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis.
Study NCT02104284 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: methacholine and mannitol bronchial challenge tests
Description: Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis.
Study NCT02998112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Fecal microbiota which was purified from fresh stool defecated by a healthy donor
Study NCT01591785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retapamulin 1% ointment
Description: Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
Study NCT01591785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
Study NCT02998112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02371811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uterine manipulator (v care)
Study NCT04526054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ENT exam
Description: ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.
Study NCT04526054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Olfactometry
Description: Olfactometry test using odorous pens (Sniffin's stick test).
Study NCT04526054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brain MRI
Description: Brain MRI focused on the olfactory bulbs (3 teslas).
Study NCT01160614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride controlled-release (ORF) tablets
Description: Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
Study NCT03370705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statin 20mg once daily per oral route,
Study NCT03370705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: Antiplatelet therapy 75mg once daily per oral route
Study NCT03370705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Agents
Description: Antiplatelet therapy 75mg once daily per oral route
Study NCT02409693 — intervention group
Intervention type: PROCEDURE
Intervention: Myringotomy with tube insertion
Study NCT03136666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil
Description: Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
Study NCT02140060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level A / Brinzolamide 1% ophthalmic suspension
Description: Fixed combination
Study NCT02140060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level B / Brinzolamide 1% ophthalmic suspension
Description: Fixed combination
Study NCT02140060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level C / Brinzolamide 1% ophthalmic suspension
Description: Fixed combination
Study NCT02140060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1% ophthalmic suspension AZOPT®
Study NCT02140060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004% ophthalmic solution TRAVATAN Z®
Study NCT00780832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Caffeine reduction
Description: Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
Study NCT00780832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic medication
Description: Detrol LA 4mg. orally, once daily for 30 days